A Swedish Observational Study on Vedolizumab Assessing Effectiveness And Healthcare Resource Utilization in Patients with Inflammatory Bowel Disease (IBD) (SVEAH) First published 12/04/2018 Last updated 25/03/2024 EU PAS number:EUPAS22735 Study Finalised